IceCure Medical Ltd (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology, announced on Friday that it received a positive vote from the FDA's Medical Device Advisory Committee Panel, with 9 out of 14 panelists supporting the benefit-risk profile of its ProSense Cryoablation System for treating early-stage low-risk invasive breast cancer.
Panelists in favor indicated that ProSense's benefits outweigh its risks when combined with adjuvant endocrine therapy. Three dissenting voters noted that adequate special controls could have swayed their support.
The panel's decision was informed by data from IceCure's ICE3 study and comparisons to lumpectomy, as well as testimonies from patients, advocates and healthcare professionals.
ProSense offers a minimally invasive alternative to traditional surgery, leveraging liquid nitrogen to destroy tumours effectively.
A final FDA decision on ProSense's marketing authorization is anticipated in Q1 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval